• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
Digging deeper: Understanding more about patient subgroups with peripheral artery disease

Digging deeper: Understanding more about patient subgroups with peripheral artery disease

by Truveta Research | Oct 4, 2022 | Research, Research Insights

Peripheral Artery Disease (PAD) is a common disease that causes the arteries in the extremities to narrow. Recently, as part of PAD Awareness Month, we investigated disparities in the frequency of common procedures used to treat PAD, known as endovascular (or...
Truveta announces collaboration with Boston Scientific

Truveta announces collaboration with Boston Scientific

by Terry Myerson, CEO | Sep 27, 2022 | News

   One of the biggest challenges the healthcare industry faces today is getting fast answers to pressing medical questions on any disease, drug, or device. To address this critical need, Truveta is a collective of 24 health systems who came together with a...
Peripheral artery disease treatment and outcomes: Disparities in frequency of revascularization procedures and incidence of adverse outcomes

Peripheral artery disease treatment and outcomes: Disparities in frequency of revascularization procedures and incidence of adverse outcomes

by Truveta Research | Sep 27, 2022 | Research, Research Insights

Peripheral artery disease (PAD) is a common disease that causes narrowing of the arteries in the extremities. The lifetime risk for Americans varies between 19-30% [1]. Many studies have shown that PAD disproportionately affects both Black or African American...

Share this


Recent posts

  • Real-world survival outcomes for CRT and CCM therapies align with landmark trials
  • Understanding the potential impact of the upcoming ACIP vote on thimerosal-containing influenza vaccines
  • Biosimilar use is on the rise – but 1 in 8 patients return to Humira

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.AcceptPrivacy notice